| SRSF2 mutations contribute to myelodysplasia by mutant-specific effects on exon recognition E Kim, JO Ilagan, Y Liang, GM Daubner, SCW Lee, A Ramakrishnan, Y Li, ... Cancer cell 27 (5), 617-630, 2015 | 629 | 2015 |
| Diverse and targetable kinase alterations drive histiocytic neoplasms EL Diamond, BH Durham, J Haroche, Z Yao, J Ma, SA Parikh, Z Wang, ... Cancer discovery 6 (2), 154-165, 2016 | 483 | 2016 |
| Modulation of splicing catalysis for therapeutic targeting of leukemia with mutations in genes encoding spliceosomal proteins SCW Lee, H Dvinge, E Kim, H Cho, JB Micol, YR Chung, BH Durham, ... Nature medicine 22 (6), 672-678, 2016 | 375 | 2016 |
| Loss of BAP1 function leads to EZH2-dependent transformation LM LaFave, W Béguelin, R Koche, M Teater, B Spitzer, A Chramiec, ... Nature medicine 21 (11), 1344-1349, 2015 | 375 | 2015 |
| Comprehensive mutational profiling of core binding factor acute myeloid leukemia N Duployez, A Marceau-Renaut, N Boissel, A Petit, M Bucci, S Geffroy, ... Blood, The Journal of the American Society of Hematology 127 (20), 2451-2459, 2016 | 272 | 2016 |
| Specific molecular signatures predict decitabine response in chronic myelomonocytic leukemia K Meldi, T Qin, F Buchi, N Droin, J Sotzen, JB Micol, D Selimoglu-Buet, ... The Journal of clinical investigation 125 (5), 1857-1872, 2015 | 197 | 2015 |
| Coordinated alterations in RNA splicing and epigenetic regulation drive leukaemogenesis A Yoshimi, KT Lin, DH Wiseman, MA Rahman, A Pastore, B Wang, ... Nature 574 (7777), 273-277, 2019 | 194 | 2019 |
| Serum 2-Hydroxyglutarate Production in IDH1- and IDH2-Mutated De Novo Acute Myeloid Leukemia: A Study by the Acute Leukemia French Association Group M Janin, E Mylonas, V Saada, JB Micol, A Renneville, C Quivoron, ... Journal of Clinical Oncology 32 (4), 297-305, 2014 | 161 | 2014 |
| Enteral feeding and early outcomes of patients undergoing allogeneic stem cell transplantation following myeloablative conditioning D Seguy, C Berthon, JB Micol, S Darré, JH Dalle, S Neuville, F Bauters, ... Transplantation 82 (6), 835-839, 2006 | 143 | 2006 |
| Frequent ASXL2 mutations in acute myeloid leukemia patients with t(8;21)/RUNX1-RUNX1T1 chromosomal translocations JB Micol, N Duployez, N Boissel, A Petit, S Geffroy, O Nibourel, ... Blood, The Journal of the American Society of Hematology 124 (9), 1445-1449, 2014 | 140 | 2014 |
| Determinants of the outcomes of patients with cancer infected with SARS-CoV-2: results from the Gustave Roussy cohort L Albiges, S Foulon, A Bayle, B Gachot, F Pommeret, C Willekens, ... Nature Cancer 1 (10), 965-975, 2020 | 126 | 2020 |
| Phase I First-in-Human Dose Escalation Study of the oral SF3B1 modulator H3B-8800 in myeloid neoplasms DP Steensma, M Wermke, VM Klimek, PL Greenberg, P Font, ... Leukemia 35 (12), 3542-3550, 2021 | 124 | 2021 |
| Somatic mutations associated with leukemic progression of familial platelet disorder with predisposition to acute myeloid leukemia I Antony-Debré, N Duployez, M Bucci, S Geffroy, JB Micol, A Renneville, ... Leukemia 30 (4), 999-1002, 2016 | 117 | 2016 |
| Chromosomal Abnormalities and Prognosis in NPM1-Mutated Acute Myeloid Leukemia: A Pooled Analysis of Individual Patient Data From Nine International Cohorts L Angenendt, C Röllig, P Montesinos, D Martínez-Cuadrón, E Barragan, ... Journal of Clinical Oncology 37 (29), 2632-2642, 2019 | 101 | 2019 |
| Results of a clinical trial of H3B-8800, a splicing modulator, in patients with myelodysplastic syndromes (MDS), acute myeloid leukemia (AML) or chronic myelomonocytic leukemia … DP Steensma, M Wermke, VM Klimek, PL Greenberg, P Font, ... Blood 134, 673, 2019 | 99 | 2019 |
| SETBP1 mutations drive leukemic transformation in ASXL1-mutated MDS D Inoue, J Kitaura, H Matsui, HA Hou, WC Chou, A Nagamachi, ... Leukemia 29 (4), 847-857, 2015 | 95 | 2015 |
| Real-life experience with CPX-351 and impact on the outcome of high-risk AML patients: a multicentric French cohort E Chiche, R Rahmé, S Bertoli, PY Dumas, JB Micol, Y Hicheri, F Pasquier, ... Blood Advances 5 (1), 176-184, 2021 | 79 | 2021 |
| ASXL2 is essential for haematopoiesis and acts as a haploinsufficient tumour suppressor in leukemia JB Micol, A Pastore, D Inoue, N Duployez, E Kim, SCW Lee, BH Durham, ... Nature communications 8 (1), 15429, 2017 | 68 | 2017 |
| JAK2 and MPL protein levels determine TPO-induced megakaryocyte proliferation vs differentiation R Besancenot, D Roos-Weil, C Tonetti, H Abdelouahab, C Lacout, ... Blood, The Journal of the American Society of Hematology 124 (13), 2104-2115, 2014 | 68 | 2014 |
| Outcome of older patients with acute myeloid leukemia in first relapse C Sarkozy, C Gardin, N Gachard, F Merabet, P Turlure, JV Malfuson, ... American journal of hematology 88 (9), 758-764, 2013 | 67 | 2013 |
